Search Results

FilmArray Respiratory Panel (RP) is a multiplexed nucleic acid test intended for use with the FilmArray instrument for the simultaneous qualitative detection and identification of multiple respiratory viral and bacterial nucleic acids in nasopharyngeal swabs (NPS) obtained from individuals suspected of respiratory tract infections. The following organism types and subtypes are identified using the FilmArray RP: Adenovirus. Coronavirus 229E, Coronavirus HKU1, Coronavirus NL63, Coronavirus OC43, Human Metapneumovirus, Influenza A, Influenza A subtype H1, Influenza A subtype H3, Influenza A subtype 2009 H1, Influenza B, Parainfluenza Virus 1, Parainfluenza Virus 2, Parainfluenza Virus 3, Parainfluenza Virus 4, Rhinovirus/Enterovirus, Respiratory Syncytial Virus, Bordetella pertussis, Chlamydophila pneumoniae, and Mycoplasma pneumoniae. The detection and identification of specific viral and bacterial nucleic acids from individuals exhibiting signs and symptoms of a respiratory infection aids in the diagnosis of respiratory infection if used in conjunction with other clinical and epidemiological information. The results of this test should not be used as the sole basis for diagnosis, treatment, or other management decisions. Negative results in the setting of a respiratory illness may be due to infection with pathogens that are not detected by this test or lower respiratory tract infection that is not detected by a nasopharyngeal swab specimen. Positive results do not rule out co-infection with other organisms; the agent(s) detected by the Film Array RP may not be the definite cause of disease. Additional laboratory testing (e.g. bacterial and viral culture, immunofluorescence, and radiography) may be necessary when evaluating a patient with possible respiratory tract infection.

The FilmArray RP System is a multiplex nucleic acid test system composed of the FilmArray instrument, the FilmArray software (preinstalled on a laptop computer) and the FilmArray RP pouch. The FilmArray RP pouch contains freeze-dried reagents to perform nucleic acid purification, reverse transcription, and nested, multiplex PCR with DNA melt analysis. The Respiratory Panel (RP) pouch identifies 20 common and emerging viral respiratory pathogens (see Table 1). A test is initiated by loading Hydration Solution and an unprocessed patient nasopharyngeal swab (NPS) specimen (i.e., specimen mixed with Sample Buffer) into the FilmArray RP pouch. The pouch contains all of the reagents required for specimen testing and analysis in a freeze-dried format; the addition of Hydration Solution and specimen/Sample Buffer Mix rehydrates the reagents. After the pouch is prepared, the FilmArray software guides the user though the steps of placing the pouch into the instrument, scanning the pouch barcode, entering the sample identification, and initiating the run. The FilmArray instrument contains a coordinated system of inflatable bladders and seal points, which act on the pouch to control the movement of liquid between the pouch blisters. When a bladder is inflated over a reagent blister. it forces liquid from the blister into connecting channels. Alternatively, when a seal is placed over a connecting channel it acts as a valve to open or close a channel. In addition, electronically controlled pneumatic pistons are positioned over multiple plungers in order to deliver the rehydrated reagents into the blisters at the appropriate times. Two Peltier devices control heating and cooling of the pouch to drive the reverse transcription reactions, the PCR reactions, and the melting curve analysis. Nucleic acid extraction occurs within the FilmArray pouch using mechanical lysis and standard magnetic bead technology. After extracting and purifying nucleic acids from the unprocessed sample, the FilmArray performs a nested multiplex PCR that is executed in two stages. During the first stage, the FilmArray performs a single, large volume, highly multiplexed reverse transcription PCR (rt-PCR) reaction. The products from first stage PCR are then diluted and combined with a fresh, primer-free master mix and a fluorescent double stranded DNA binding dye (LC Green®Plus, Idaho Technology). This second master mix solution, is then distributed to each well of the array. Array wells contain sets of primers designed specifically to amplify sequences internal to the PCR products generated during the first stage PCR reaction. The second stage PCR, or nested PCR, is performed in singleplex fashion in each well of the array. At the conclusion of the 200 stage PCR, the array is interrogated by melting curve analysis for the detection of signature amplicons denoting the presence of specific viral or bacterial targets. A digital camera placed in front of the second stage PCR captures fluorescent images of the PCR reactions in real time. The FilmArray software automatically interprets the results of each DNA melting curve analysis and combines the data with the results of the internal pouch controls to provide a test result for each organism on the panel.

Acceptance Criteria and Device Performance Study for FilmArray® Respiratory Panel (RP)

This document describes the acceptance criteria and supporting studies for the FilmArray® Respiratory Panel (RP) device with added assays for Coronavirus OC43, Coronavirus 229E, Bordetella pertussis, Mycoplasma pneumoniae, and Chlamydophila pneumoniae.

1. Table of Acceptance Criteria and Reported Device Performance

The provided document does not explicitly state pre-defined acceptance criteria (e.g., "sensitivity must be >90%"). Instead, the clinical performance is presented as observed Positive Percent Agreement (PPA) and Negative Percent Agreement (NPA) with 95% confidence intervals. The reproducibility study shows percent agreement with expected results at various concentrations. For clarity, we will present the key performance metrics observed in the clinical and archived specimen studies as "reported device performance."

(N/A - Not Applicable, LoD - Limit of Detection)

2. Sample Sizes Used for the Test Set and Data Provenance

The evaluation for the newly added assays was conducted through a combination of prospective clinical studies, retrospective testing of archived clinical specimens, and contrived specimens.

• Prospective Clinical Study:

  • Sample Size: 1117 subjects (initially 1144 enrolled, 27 withdrawn or omitted).
  • Data Provenance: 3 U.S. clinical sites.
  • Retrospective or Prospective: Prospective. The study spanned two respiratory seasons (December 2009 - May 2010 and September 2010 - January 2011).

• Archived Specimens Study (for B. pertussis, Coronavirus 229E, Coronavirus OC43, or M. pneumoniae):

  • Sample Size: 305 total specimens.
  • Data Provenance: Not explicitly stated but implied to be from various sources, likely within the U.S., as they were "preselected archived samples."
  • Retrospective or Prospective: Retrospective.

• Contrived C. pneumoniae Specimens Study:

  • Sample Size: 100 specimens (50 spiked, 50 unspiked).
  • Data Provenance: Residual specimens from the prospective clinical study, spiked with C. pneumoniae.
  • Retrospective or Prospective: Contrived/Spiked.

3. Number of Experts Used to Establish the Ground Truth for the Test Set and Their Qualifications

The document describes the reference/comparator methods used to establish the ground truth, rather than directly mentioning "experts" in the context of adjudication for individual test results.

• Method: For Coronavirus 229E, Coronavirus OC43, B. pertussis, C. pneumoniae, and M. pneumoniae, the ground truth was established by composite comparator methods consisting of two analytically validated PCR assays followed by bi-directional sequencing.
  • "True" positives were defined as samples with bi-directional sequencing data meeting pre-defined quality acceptance criteria and matching NCBI GenBank database sequences.
  • "True" negatives were defined as samples negative by both comparator PCR assays.
• Number of Experts: Not explicitly stated as a number of human experts adjudicating each case. The "experts" implied are the skilled laboratory personnel performing and interpreting the bi-directional sequencing, which is a highly technical molecular biology method. Their qualifications would implicitly be in molecular diagnostics and sequence analysis.

4. Adjudication Method for the Test Set

The adjudication method relies on the described composite comparator methods:

• Method: Two independent PCR assays targeting different sequences, followed by bi-directional sequencing for confirmation.
• Rule: "True" positives were confirmed by sequencing matching GenBank. "True" negatives were confirmed by negativity in both PCR assays. Discrepant results between the FilmArray RP and the initial comparator PCRs were further investigated using bi-directional sequencing (as seen in the footnotes for discrepancy investigations in Table 4).

This is a form of adjudicated ground truth based on a robust laboratory method rather than human consensus interpretation of device output.

5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study Was Done

No, a Multi-Reader Multi-Case (MRMC) comparative effectiveness study was not done.

This device is an automated multiplex nucleic acid test. Its performance is evaluated against reference laboratory methods, not by comparing human reader performance with and without AI assistance. The readout is qualitative (presence/absence of target nucleic acid), and interpretation is automated by the device's software.

6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) Was Done

Yes, a standalone performance study was done.

The clinical performance data (PPA, NPA) presented in Tables 4, 8, and 9 reflects the performance of the FilmArray RP system (including the algorithm responsible for interpreting the raw data and providing a result) operating independently without human modification or interpretation of the final result. The system's software automatically interprets results based on melting curve analysis and internal controls.

7. The Type of Ground Truth Used

The primary type of ground truth used was expert-defined laboratory gold standard:

• Clinical and Archived Specimen Studies: Ground truth was established using composite comparator methods comprising two analytically validated PCR assays followed by bi-directional sequencing. This is a highly robust and specific laboratory reference method.
• Contrived C. pneumoniae Specimens: Ground truth was established by spiking known concentrations of the pathogen into clinical matrix, and also by using unspiked controls.

8. The Sample Size for the Training Set

The document does not explicitly state the sample size for the training set used to develop the FilmArray RP algorithms for the newly added assays. Regulatory submissions typically focus on the performance of the final, locked algorithm on independent test sets (as described in this document), rather than detailing the internal development and training processes.

9. How the Ground Truth for the Training Set Was Established

As the document does not provide details on a specific "training set," it also does not describe how the ground truth for any training set was established. It's common for diagnostic device development to use well-characterized positive and negative specimens, often confirmed by highly sensitive and specific laboratory methods (similar to the comparator methods described for the test set), for initial algorithm development and optimization.

Ask a specific question about this device

The Joint Biological Agent Identification and Diagnostic System (JBAIDS) Q Fever Detection Kit is a qualitative real-time polymerase chain reaction (PCR) test kit intended to identify and detect target DNA sequence from Coxiella burnetii in serum collected from individuals suspected of having acute Q fever, typically 7-10 days after onset of symptoms or before antibody formation. This in vitro diagnostic (IVD) test is intended to aid in the diagnosis of Q fever in individuals presenting with signs and symptoms of acute Q fever when used in conjunction with other clinical and laboratory findings. This kit is only intended to aid in the diagnosis of Q fever of patients presenting in the acute stage of the disease. Negative results do not preclude C. burnetii infection and should not be used as the sole basis for diagnosis, treatment or other management decisions.

The JBAIDS Q Fever assay is run on the JBAIDS instrument using the Diagnostic Wizard. Results are for the presumptive identification of C. burnetii in conjunction with serology and/or other laboratory tests. The following considerations also apply:

• The diagnosis of acute Q fever must be made based on history, signs, symptoms, exposure likelihood, and other laboratory evidence, in addition to the identification of C. burnetii from serum specimens.
• Sensitivity is decreased by ~25-40%, with no change in specificity, if the sample is collected after the patient has formed specific antibodies to C. burnetii, typically 7-10 days after onset of symptoms.
• The definitive identification of C. burnetii from serum specimens requires additional testing and confirmation procedures in consultation with public health or other authorities for whom reports are required.

The Joint Biological Agent Identification and Diagnostic System (JBAIDS) Q Fever Detection Kit is a fully integrated in-vitro diagnostic (IVD) system composed of the JBAIDS instrument with laptop computer, software, a freeze-dried reagent assay for the qualitative detection of pathogenic Coxiella burnetii, and 2 different sample preparation protocols for isolating target DNA from serum. Use of the JBAIDS DNA Extraction Control kit (not included) is also recommended.

The JBAIDS instrument, using Polymerase Chain Reaction (PCR) technology, is a portable thermocycler and real-time fluorimeter. The JBAIDS Q Fever Detection Kit is specially designed for PCR in glass capillaries using the JBAIDS instrument and hydrolysis probes for sequence-specific detection of the C. burnetii IS1111 DNA target.

The reagent kit contains 3 different types of freeze-dried reagent vials: Positive Controls, Negative Controls, and Unknowns (used for testing the patient sample). Each JBAIDS assay requires a Positive and Negative Control, and each sample is tested using an Unknown reagent vial which contains a multiplexed target and inhibition control (IC) assay.

Prior to testing, serum samples are purified using the Idaho Technology IT 1-2-3™ QFLOW or IT 1-2-3™ Platinum Path Sample Purification Kit. The resulting purified sample is added to an Unknown reagent vial, along with reconstitution buffer. A Positive Control and a Negative Control vial are prepared using reconstitution buffer and reagent grade water. Aliquots from each reagent vial are transferred to 2 reaction capillaries that are tested together in the JBAIDS instrument. The instrument is programmed to perform heating and cooling cycles that drive the PCR process. The heating and cooling cycles are generated using a heating coil and varying fan speeds. Fluorescence emission is monitored over 1 of 3 wavelengths, and the instrument software interprets the change in fluorescence to determine whether the target DNA is present.

When the organism is present, a fragment of C. burnetii DNA is amplified using specific primers. The amplicon is detected by fluorescence using a specific hydrolysis probe. The hydrolysis probe contains a short oligonucleotide that hybridizes to an internal sequence of the amplified fragment during the annealing phase of the PCR cycle. This probe has the 5' and 3' ends labeled with a reporter dye and a quenching dye, respectively. When the probe hybridizes to the specific DNA target, the Taq polymerase enzyme replicating the targetspecific DNA hydrolyzes the probe, which separates the two fluorophores, thus allowing the reporter dye to fluoresce. Fluorescence is monitored at a wavelength of 530 nm. Inhibition is monitored using an internal inhibition control. The inhibition control consists of a linearized plasmid containing an artificial intervening sequence flanked by target assay primer sequences. Similar to the target, the IC probe also has the 5' and 3' ends labeled with a reported and quenching dye, respectively. Hydrolysis of the IC probe during amplification is monitored at a wavelength of 705 nm.

The level of fluorescence from each unknown sample and control is measured by the JBAIDS instrument. JBAIDS Software analyzes fluorescence amplification curves and reports results as Positive, Negative, Inhibited, or Uncertain. A failure of the Positive or Negative Control will result in the entire run being called Invalid. Failure of the Inhibition Control when no target amplification is observed yields an Inhibited result for the associated sample and requires retesting of that sample. A positive result for the target will override an inhibited result.

Here's a breakdown of the acceptance criteria and study details for the JBAIDS Q Fever Detection Kit, based on the provided text:

1. Table of Acceptance Criteria and Reported Device Performance

The document does not explicitly state formal "acceptance criteria" in a quantitative, pre-defined manner for the clinical study. Instead, it presents performance characteristics (sensitivity and specificity) from a clinical trial. The analytical performance (LoD and exclusivity) directly reports observed results without listing specific target criteria.

• 10/10 (100%) of isolates in C. burnetii inclusivity panel correctly identified at determined system LoD. |
  | • Exclusivity (Specificity) | No cross-reactivity with phylogenetically related or commonly found organisms. | - 22 of 22 non-C. burnetii strains tested in exclusivity panel were negative at high concentration.
• In silico evaluation of Ehrlichia and Neorickettsia indicated no cross-reactivity. |
  | • Reproducibility | Highly reproducible test results at or above LoD (Implied: High agreement with expected positive results; low %CV for Cp values). | - Agreement with Expected Positive Results (Detection ≥ LoD): 100% (204/204) across all sites and both purification kits (95% CI: 98.2-100.0%).
• Agreement at LoD/15 (low concentration): 52% (53/102) across all sites and both purification kits (95% CI: 41.8-62.0%).
• Average Cp %CV: Low %CV values for 5X LoD, LoD, and LoD/15, indicating consistent Cycle threshold values. Percent CV for 5X LoD and LoD was generally below 3%. |
  | Clinical Studies | | |
  | • Clinical Sensitivity | Detect C. burnetii in samples from acute Q fever patients (Implied: Reasonable detection rate, especially prior to antibody formation). | For samples prior to seroconversion (Acute Q Fever, Seronegative):
• Site 1: Platinum Path: 47% (9/19; 95% CI=24-71%); QFLOWdna: 29% (5/17; 95% CI=10-56%).
• Site 2: Platinum Path: 77% (20/26; 95% CI=56-91%); QFLOWdna: 81% (22/27; 95% CI=62-94%). (Note: Sensitivity decreased significantly in seropositive samples). |
  | • Clinical Specificity | No false positives in samples without C. burnetii (Implied: High negative predictive value). | For serology negative samples (no antibody to C. burnetii):
• Site 1: Platinum Path: 100% (40/40; 95% CI=91-100%); QFLOWdna: 100% (39/39; 95% CI=91-100%).
• Site 2: Platinum Path: 100% (71/71; 95% CI=95-100%); QFLOWdna: 100% (72/72; 95% CI=95-100%).
• Overall, 306/307 (99.7%) of serology negative samples gave expected negative results. One false positive was observed from a sample that failed to show a four-fold antibody titer rise. |

2. Sample Size Used for the Test Set and Data Provenance

• Test Set Description: Banked, frozen serum specimens.
• Data Provenance: The specimens were sequentially received during a specified time period. The clinical study involved three independent laboratories located in distinct geographical regions: Australia, France, and the Netherlands. This indicates the data is retrospective.
• Total Subjects Evaluated: 749 subjects.
• Subjects Included in Analysis: 465 subjects.
• Exclusions:
  • 86 for inconclusive or incomplete serology.
  • 21 due to environmental contamination.
  • 7 for inconclusive JBAIDS results.
  • All 170 samples tested at Site 3 due to deviations from the study protocol.
• Total Final Test Results (after purification):
  • Platinum Path: 324 results (170 from serology positive, 154 from serology negative).
  • QFLOWdna: 324 results (171 from serology positive, 153 from serology negative).
    (Note: 183 specimens had adequate volume for purification by both methods, contributing to the total results.)
• Breakdown for Sensitivity/Specificity Calculation:
  • Seronegative, No Antibody to C. burnetii (Specificity):
    • Site 1: 40 (Platinum Path) + 39 (QFLOWdna) = 79 samples
    • Site 2: 71 (Platinum Path) + 72 (QFLOWdna) = 143 samples
    • Total: 222 samples
  • Seronegative, Failed 4-fold Antibody Rise (where 1 false positive occurred): 85 samples
  • Seropositive (Sensitivity, where seroconversion occurred):
    • Site 1: 19 (Platinum Path) + 17 (QFLOWdna) = 36 samples
    • Site 2: 26 (Platinum Path) + 27 (QFLOWdna) = 53 samples
    • Total: 89 samples (for samples exhibiting seroconversion)

3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications of Those Experts

The ground truth for the clinical study was established by standard paired serological testing for Q fever, which had been previously performed on the banked specimens.
The document does not specify the number or qualifications of experts who performed or interpreted this serological testing. It refers to "standard paired serological testing," implying established laboratory procedures.

4. Adjudication Method for the Test Set

The document does not describe an explicit "adjudication method" involving independent review of results for the clinical study. The ground truth was based on the outcome of "standard paired serological testing." The JBAIDS results were compared against this serological ground truth. There is no mention of multiple experts reviewing individual cases or a conciliation process if disagreements arose.

5. If a Multi Reader Multi Case (MRMC) Comparative Effectiveness Study was Done, If So, What was the effect size of how much human readers improve with AI vs without AI assistance

No, an MRMC comparative effectiveness study involving human readers and AI assistance was not done.
The JBAIDS Q Fever Detection Kit is a real-time PCR assay, an in vitro diagnostic (IVD) device, not an AI-powered diagnostic imaging or interpretation system that would typically involve human "readers." The device provides automated test interpretation and report generation.

6. If a Standalone (i.e. algorithm only without human-in-the-loop performance) was done

Yes, a standalone performance evaluation was done. The JBAIDS Q Fever Detection Kit is described as a "fully integrated in-vitro diagnostic (IVD) system" with "automated test interpretation and report generation." The clinical and analytical studies measure the performance of this system operating in a standalone capacity, producing "Positive, Negative, Inhibited, or Uncertain" results based on fluorescence amplification curves. While human operators are involved in sample preparation and loading, the interpretation of the PCR data is handled by the instrument's software algorithms, without human interpretative input into individual test results.

7. The Type of Ground Truth Used

The ground truth used for the clinical study was based on standard paired serological testing for Q fever.
Specifically, for establishing sensitivity, it relied on samples exhibiting a four-fold rise in antibodies (indicating seroconversion, a definitive sign of infection). For establishing specificity, it relied on samples with no antibody to C. burnetii confirmed by serology.

8. The Sample Size for the Training Set

The document does not specify the sample size for a training set. As this is a molecular diagnostic kit (PCR), the "training" would typically involve optimization and validation of primers, probes, and reaction conditions rather than machine learning on a dataset with ground truth. The performance data presented (LoD, exclusivity, reproducibility, clinical studies) are evaluations of the finalized kit.

9. How the Ground Truth for the Training Set was Established

Since no explicit "training set" for an algorithm is mentioned or implied, the question of how its ground truth was established is not applicable in the typical sense of machine learning. The kit's design and analytical performance (e.g., selection of primers and probes for C. burnetii IS1111 DNA sequences) would have been developed against known strains and samples, but these are part of assay development and analytical validation, not a separate "training set" with ground truth in the context of an AI/ML device.

Ask a specific question about this device

FilmArray Respiratory Panel (RP) is a multiplexed nucleic acid test intended for use with the FilmArray instrument for the simultaneous qualitative detection and identification of multiple respiratory viral nucleic acids in nasopharyngeal swabs (NPS) obtained from individuals suspected of respiratory tract infections. The following virus types and subtypes are identified using the FilmArray RP: Adenovirus, Coronavirus HKU1, Coronavirus NL63, Human Metapneumovirus, Influenza A, Influenza A subtype H1, Influenza A subtype H3, Influenza A subtype 2009 H1, Influenza B, Parainfluenza Virus 1, Parainfluenza Virus 2, Parainfluenza Virus 3, Parainfluenza Virus 4, Rhinovirus/Enterovirus, and Respiratory Syncytial Virus. The detection and identification of specific viral nucleic acids from individuals exhibiting signs and symptoms of a respiratory infection aids in the diagnosis of respiratory viral infection if used in conjunction with other clinical and epidemiological information. Negative results do not preclude respiratory viral infection and should not be used as the sole basis for diagnosis, treatment or other management decisions. Positive results do not rule out bacterial infection or co-infection with other organisms. The agent detected may not be the definite cause of disease. The use of additional laboratory testing (e.g. bacterial and viral culture, immunofluorescence, and radiography) and clinical presentation must be taken into consideration in order to obtain the final diagnosis of respiratory infection.

Due to seasonal prevalence, performance characteristics for Influenza A/H1, Influenza A/H3, Influenza A/2009 H1, Influenza B, Parainfluenza Virus 1, Parainfluenza Virus 2, and Parainfluenza Virus 4 were established primarily with retrospective clinical specimens.

Due to the genetic similarity between human Rhinovirus and Enterovirus, the FilmArray RP cannot reliably differentiate them. A positive FilmArray RP Rhinovirus/Enterovirus result should be followed-up using an alternate method (e.g. cell culture or sequence analysis).

The FilmArray RP detects Adenovirus species C serotype 2 and serotype 6 with reduced sensitivity. It is recommended that specimens found to be negative for Adenovirus after examination using FilmArray RP be confirmed by an alternate method (e.g. FDA cleared molecular test or cell culture).

Performance characteristics for influenza A were established when influenza A/2009 H1N1, A/H1, and A/H3 were the predominant influenza A viruses in circulation. When other influenza A viruses are emerging, performance characteristics may vary. If infection with a novel influenza A virus is suspected based on current clinical and epidemiological screening criteria recommended by public health authorities, specimens should be collected with appropriate infection control precautions for novel virulent influenza viruses and sent to state or local health departments for testing. Viral culture should not be attempted in these cases unless a BSL 3+ facility is available to receive and culture specimens.

The FilmArray RP System is a multiplex nucleic acid test system composed of the FilmArray instrument, the FilmArray software (preinstalled on a laptop computer) and the FilmArray RP pouch. The FilmArray RP pouch contains freeze-dried reagents to perform nucleic acid purification, reverse transcription, and nested, multiplex PCR with DNA melt analysis. The Respiratory Panel (RP) pouch identifies 15 common and emerging viral respiratory pathogens (see Table 1).

A test is initiated by loading Hydration Solution and an unprocessed patient nasopharyngeal swab (NPS) specimen (i.e. specimen mixed with Sample Buffer) into the FilmArray RP pouch. The pouch contains all of the reagents required for specimen testing and analysis in a freeze-dried format; the addition of Hydration Solution and Sample/Buffer Mix rehydrates the reagents. After the pouch is prepared, the FilmArray software guides the user though the steps of placing the pouch into the instrument, scanning the pouch barcode, entering the sample identification and initiating the run.

The FilmArray instrument contains a coordinated system of inflatable bladders and seal points, which act on the pouch to control the movement of liquid between the pouch blisters. When a bladder is inflated over a reagent blister, it forces liquid from the blister into connecting channels. Alternatively, when a seal is placed over a connecting channel it acts as a valve to open or close a channel. In addition, electronically controlled pneumatic pistons are positioned over multiple plungers in order to deliver the rehydrated reagents into the blisters at the appropriate times. Two Peltier devices control heating and cooling of the pouch to drive the reverse transcription reactions, the PCR reactions, and the melting curve analysis.

Nucleic acid extraction occurs within the FilmArray pouch using mechanical lysis and standard magnetic bead technology. After extracting and purifying nucleic acids from the unprocessed sample, the FilmArray performs a nested multiplex PCR that is executed in two stages. During the first stage, the FilmArray performs a single, large volume, highly multiplexed reverse transcription PCR (rt-PCR) reaction. The products from first stage PCR are then diluted and combined with a fresh, primer-free master mix and a fluorescent double stranded DNA binding dve (LC Green@Plus, Idaho Technology). This second master mix solution, is then distributed to each well of the array. Array wells contain sets of primers designed specifically to amplify sequences internal to the PCR products generated during the first stage PCR reaction. The second stage PCR, or nested PCR, is performed in singleplex fashion in each well of the array. At the conclusion of the 200 stage PCR, the array is interrogated by melting curve analysis for the detection of signature amplicons denoting the presence of specific viral or bacterial targets A digital camera placed in front of the second stage PCR captures fluorescent images of the PCR reactions in real time.

The FilmArray software automatically interprets the results of each DNA melting curve analysis and combines the data with the results of the internal pouch controls to provide a test result for each organism on the panel.

Here's a breakdown of the acceptance criteria and the study that proves the device meets them, based on the provided text:

Device: FilmArray Respiratory Panel (RP) System

Purpose of 510(k) submission: To support unmasking of test results for the Parainfluenza Virus 1, 2, and 4 (PIV1, PIV2, PIV4) assays in the FilmArray RP.

1. Table of Acceptance Criteria and Reported Device Performance

The acceptance criteria are generally implied standards for diagnostic tests (e.g., high sensitivity and specificity). The reported device performance is directly from the study results.

2. Sample Size Used for the Test Set and Data Provenance

Clinical Performance Study (Prospective):

• Sample Size: 1117 subjects (after exclusions) from an initial enrollment of 1144.
• Data Provenance: Prospective study conducted at 3 U.S. clinical sites. Enrollment spanned December 2009 - May 2010 and September 2010 - January 2011 (two respiratory seasons).

Archived Specimens Study (Retrospective):

• Sample Size: 147 confirmed specimens tested (from 168 initially selected).
• Data Provenance: Retrospective study using preselected archived clinical nasopharyngeal swab (NPS) specimens. The origin of these archived samples is not specified beyond being "preselected" and from "one source" (a pediatric hospital mentioned for age range).

3. Number of Experts Used to Establish the Ground Truth for the Test Set and Their Qualifications

The term "experts" in the context of diagnostic assay ground truth typically refers to reference laboratory personnel or clinicians involved in the gold standard method. The document describes the methods used to establish ground truth rather than explicitly stating the number and qualifications of individuals.

For Parainfluenza Virus 1 and 2 (Clinical Study):

• Ground Truth Method: Viral culture followed by DFA (Direct Fluorescent Antibody) identification.
• Implicit Expertise: Laboratory technicians/virologists skilled in viral culture techniques and DFA interpretation. No specific number or qualifications (e.g., years of experience) mentioned.

For Parainfluenza Virus 4 (Clinical Study):

• Ground Truth Method: Viral culture followed by one analytically validated PCR assay with bi-directional sequence confirmation.
• Implicit Expertise: Laboratory technicians/virologists skilled in viral culture, PCR amplification, and sequence analysis. No specific number or qualifications mentioned.

For Archived Specimens Study:

• Ground Truth Method: Analyte-specific PCR and bi-directional sequencing.
• Implicit Expertise: Laboratory personnel proficient in molecular diagnostic techniques and sequence analysis. No specific number or qualifications mentioned.

4. Adjudication Method for the Test Set

The document does not explicitly describe an "adjudication method" in the typical sense of multiple experts reviewing discordant results. Instead, it describes how "true" positive/negative status was determined based on the outcomes of the reference methods:

• Clinical Study (PIV1, PIV2, PIV4):
  • For PIV1 and PIV2, "True" positives/negatives were defined by the viral culture with DFA results.
  • For PIV4, "True" positives were defined by bi-directional sequencing data matching NCBI GenBank sequences from viral culture material. "True" negatives were defined by negative results from the comparator PCR assay on viral culture material.
  • Discrepancies between the FilmArray RP and comparator methods were sometimes further investigated (e.g., PIV1 was identified in one discordant specimen by bi-directional sequence analysis; PIV2 in false positive specimens by bi-directional sequencing). This suggests a form of post-hoc review for discrepant results, but not a front-end adjudication process by multiple independent experts defining ground truth prior to or independent of the reference method.
• Archived Specimens Study: Ground truth was established by "analyte specific PCR and bi-directional sequencing" prior to FilmArray RP testing. The study design meant users testing with FilmArray RP were "blinded as to the expected test result." This indicates the ground truth was predetermined by molecular methods.

5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study was done

No, a Multi-Reader Multi-Case (MRMC) comparative effectiveness study was not performed. This study focuses on the diagnostic performance of the device itself against reference methods, not on comparing human reader performance with and without AI assistance. The FilmArray RP is an automated diagnostic system, not an AI-assisted interpretation tool for human readers.

6. If a Standalone (Algorithm Only Without Human-in-the-Loop Performance) was done

Yes, the study describes the standalone performance of the FilmArray RP System.

• The FilmArray RP is a fully automated system from specimen loading to result interpretation. The "FilmArray software automatically interprets the results of each DNA melting curve analysis and combines the data with the results of the internal pouch controls to provide a test result for each organism on the panel."
• The clinical sensitivity, specificity, and analytical studies (LoD, inclusivity, specificity, precision, interference) all evaluate the performance of this automated system directly against established reference methods or controlled conditions, without human interpretation as part of the primary diagnostic output.

7. The Type of Ground Truth Used

• Clinical Performance Study:
  • Expert Consensus: Not explicitly stated as consensus among multiple experts. The ground truth was established by viral culture followed by DFA (PIV1, PIV2) and viral culture followed by analytically validated PCR with bi-directional sequence confirmation (PIV4). These are established laboratory diagnostic methods often considered gold standards for viral detection at the time.
  • Pathology: Not applicable, as this is a viral detection assay, not tissue pathology.
  • Outcomes Data: Not primarily outcomes data, but a direct comparison to laboratory reference methods for pathogen presence.
• Archived Specimens Study:
  • Molecular Confirmation: Ground truth was established using analyte-specific PCR and bi-directional sequencing. This is a highly specific molecular method for confirming the presence or absence of viral nucleic acid.

8. The Sample Size for the Training Set

The document does not specify a training set size because it describes a diagnostic device validation study, not a machine learning model development study with separate training and testing sets. The FilmArray RP is a molecular diagnostic assay using pre-programmed algorithms for interpretation, not a learnable AI algorithm that requires a "training set" in the machine learning sense. The device's internal algorithms and reagents are developed, and then validated with the clinical and analytical performance studies described.

9. How the Ground Truth for the Training Set Was Established

As noted above, there is no "training set" in the context of machine learning for this device. The device's operational parameters and interpretive logic are presumably established during its development phase using a combination of scientific principles, laboratory experiments, and internal validation, rather than through labeled training data as used in AI.

Ask a specific question about this device

The FilmArray Respiratory Panel (RP) is a multiplexed nucleic acid test intended for use with the FilmArray instrument for the simultaneous qualitative detection and identification of multiple respiratory viral nucleic acids in nasopharyngeal swabs (NPS) obtained from individuals suspected of respiratory tract infections. The following virus types and subtypes are identified using the FilmArray RP: Adenovirus, Coronavirus HKU1, Coronavirus NL63, Human Metapneumovirus, Influenza A, Influenza A subtype H1, Influenza A subtype H3, Influenza A subtype 2009 H1, Influenza B, Parainfluenza virus 3, Rhinovirus/Enterovirus, and Respiratory Syncytial Virus. The detection and identification of specific viral nucleic acids from individuals exhibiting signs and symptoms of a respiratory infection aids in the diagnosis of respiratory infection if used in conjunction with other clinical and epidemiological information. Negative results do not preclude respiratory infection and should not be used as the sole basis for diagnosis, treatment or other management decisions. Positive results do not rule out bacterial infection or co-infection with other organisms. The agent detected may not be the definite cause of disease. The use of additional laboratory testing (e.g. bacterial and viral culture, immunofluorescence, and radiography) and clinical presentation must be taken into consideration in order to obtain the final diagnosis of respiratory infection.

Due to seasonal prevalence, performance characteristics for Influenza A/H1, Influenza A/H3, Influenza A/2009 H1, and Influenza B were established primarily with retrospective clinical specimens.

Due to the genetic similarity between human Rhinovirus and Enterovirus, the FilmArray RP cannot reliably differentiate them. A positive FilmArray RP Rhinovirus/Enterovirus result should be followed-up using an alternate method (e.g. cell culture or sequence analysis).

The FilmArray RP detects Adenovirus species C serotype 6 with reduced sensitivity. It is recommended that specimens found to be negative for Adenovirus after examination using FilmArray RP be confirmed by an alternate method (e.g. FDA cleared molecular test or cell culture).

Performance characteristics for influenza A were established when influenza A/2009 H1N1, A/H1, and A/H3 were the predominant influenza A viruses in circulation. When other influenza A viruses are emerging, performance characteristics may vary. If infection with a novel influenza A virus is suspected based on current clinical and epidemiological screening criteria recommended by public health authorities, specimens should be collected with appropriate infection control precautions for novel virulent influenza viruses and sent to state or local health departments for testing. Viral culture should not be attempted in these cases unless a BSL 3+ facility is available to receive and culture specimens.

The FilmArray RP System is multiplex nucleic acid test system composed of the FilmArray instrument, the FilmArray software (preinstalled on a laptop computer) and the FilmArray RP pouch. The FilmArray RP pouch contains freeze-dried reagents to perform nucleic acid purification, reverse transcription, and nested, multiplex PCR with DNA melt analysis. The Respiratory Panel (RP) pouch identifies 12 common and emerging viral respiratory pathogens (see Table 1).

A test is initiated by loading Hydration Solution and an unprocessed patient nasopharyngeal swab (NPS) specimen (i.e. specimen mixed with Sample Buffer) into the FilmArray RP pouch. The pouch contains all of the reagents required for specimen testing and analysis in a freeze-dried format; the addition of Hydration Solution and Sample/Buffer Mix rehydrates the reagents. After the pouch is prepared, the FilmArrav software guides the user though the steps of placing the pouch into the instrument, scanning the pouch barcode, entering the sample identification and initiating the run.

The FilmArray instrument contains a coordinated system of inflatable bladders and seal points, which act on the pouch to control the movement of liquid between the pouch blisters. When a bladder is inflated over a reagent blister, it forces liquid from the blister into connecting channels. Alternatively, when a seal is placed over a connecting channel it acts as a valve to open or close a channel. In addition, electronically controlled pneumatic pistons are positioned over multiple plungers in order to deliver the rehydrated reagents into the blisters at the appropriate times. Two Peltier devices control heating and cooling of the pouch to drive the reverse transcription reactions, the PCR reactions, and the melting curve analysis.

Nucleic acid extraction occurs within the FilmArray pouch using mechanical lysis and standard magnetic bead technology. After extracting and purifying nucleic acids from the unprocessed sample, the FilmArray performs a nested multiplex PCR that is executed in two stages. During the first stage, the FilmArray performs a single, large volume, highly multiplexed reverse transcription PCR (rt-PCR) reaction. The products from first stage PCR are then diluted and combined with a fresh, primer-free master mix and a fluorescent double stranded DNA binding dye (LC Green@Plus, Idaho Technology). This second master mix solution, is then distributed to each well of the array. Array wells contain sets of primers designed specifically to amplify sequences internal to the PCR products generated during the first stage PCR reaction. The second stage PCR, or nested PCR, is performed in singleplex fashion in each well of the array. At the conclusion of the 200 stage PCR, the array is interrogated by melting curve analysis for the detection of signature amplicons denoting the presence of specific viral or bacterial targets A digital camera placed in front of the second stage PCR captures fluorescent images of the PCR reactions in real time.

The FilmArray software automatically interprets the results of each DNA melting curve analysis and combines the data with the results of the internal pouch controls to provide a test result for each organism on the panel.

Here's an analysis of the provided text, focusing on acceptance criteria and supporting study details:

1. Table of Acceptance Criteria and Reported Device Performance

The document does not explicitly state pre-defined "acceptance criteria" in a numerical target for metrics like sensitivity or specificity. However, it presents the reported clinical sensitivity (Positive Percent Agreement - PPA) and specificity (Negative Percent Agreement - NPA) for each detected organism from two studies: a prospective clinical study and an archived specimen study. The implicit acceptance criteria would be for these values to be high, ideally close to 100%, and for the 95% Confidence Intervals (CI) to be acceptably narrow.

Table: Reported Device Performance (Clinical Studies)

2. Sample Sizes and Data Provenance

• Test Set (Clinical Performance):
  • Prospective Clinical Study:
    • Sample Size: 853 subjects (from an initial enrollment of 857).
    • Data Provenance: 3 U.S. clinical sites, prospective data collected from December 2009 through May 2010.
  • Archived Specimen Study:
    • Sample Size: 349 archived clinical NPS specimens were confirmed to contain or lack the analyte of interest (from 400 initially selected).
    • Data Provenance: Retrospective, preselected archived clinical NPS specimens. Age demographics provided (e.g., 89 (25.5%) ≤5 years, 188 (53.9%) unknown age from a pediatric hospital). Country of origin is implied to be U.S. from clinical sites and some strains are from particular US states, but not explicitly stated for all archived samples.

3. Number of Experts and Qualifications for Ground Truth (Test Set)

The document primarily relies on comparator methods for establishing ground truth, rather than a direct count of human expert consensus.

• For Adenovirus, Influenza A, Influenza B, Parainfluenza virus 3, Respiratory Syncytial Virus (Prospective Study):
  • Ground Truth Method: Viral culture followed by DFA (Fluorescent Antibody) identification. "True" positives/negatives were defined based on these comparator methods.
• For FluA/H1, FluA/H3, FluA/2009 H1 (Prospective Study):
  • Ground Truth Method: Viral culture followed by one analytically validated PCR assay with bi-directional sequence confirmation. The comparator PCR assays were designed to amplify different sequences than the FilmArray assays. "True" positives/negatives were based on cultural positivity for Influenza A and bi-directional sequencing results matching NCBI GenBank entries.
• For Human Rhinovirus, Coronavirus NL63, Coronavirus HKU1, Human Metapneumovirus (Prospective Study):
  • Ground Truth Method: A "predetermined algorithm that used composite comparator methods" consisting of two analytically validated PCR assays followed by bi-directional sequencing. "True" positives/negatives were based on bi-directional sequencing data matching NCBI GenBank entries or negative results from both comparator PCR assays.
• For Archived Specimen Study:
  • Ground Truth Method: Analyte-specific PCR and bi-directional sequencing were used to confirm the presence or absence of the analyte of interest in each specimen prior to FilmArray RP testing.

The document does not specify the number of experts or their qualifications for interpreting the DFA, viral culture, PCR, or sequencing results. It states these are "analytically validated" assays, implying expert input in their validation and interpretation, but provides no direct detail on the human experts involved in establishing the ground truth for this specific study.

4. Adjudication Method for the Test Set

The document describes comparator methods for defining "true" positive/negative results. For the clinical performance sections:

• For categories like Adenovirus through RSV in the prospective study, ground truth was set by viral culture + DFA. Discrepancies between FilmArray RP and the comparator method were further investigated (e.g., footnoted retesting and bi-directional sequence analysis for false positives/negatives). For example, "Adenoviruses were identified in 13/14 false positive specimens using bi-directional sequence analysis." This implies adjudication by molecular methods (PCR and sequencing) was used to resolve discrepancies or to further confirm findings where FilmArray differed from the initial comparator method.
• For Influenza A subtypes and other viruses (Rhinovirus, etc.), the ground truth was already a composite of PCR and bi-directional sequencing, suggesting internal resolution of complex cases within that ground truth establishment process.

The "archived specimen study" explicitly states that the presence or absence of the analyte was confirmed using analyte-specific PCR and bi-directional sequencing prior to FilmArray RP testing, which serves as a highly robust ground truth.

5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study

No. The study is a diagnostic performance evaluation comparing the device (FilmArray RP) against established laboratory methods (viral culture, PCR, sequencing) for detecting respiratory pathogens. It does not involve human readers interpreting results with or without AI assistance, or quantify the effect size of human improvement. This is a standalone diagnostic test evaluation.

6. Standalone Performance Study (Algorithm Only)

Yes, the clinical performance studies (prospective and archived specimen) describe the standalone performance of the FilmArray RP system. The device is automated with "automated test interpretation and report generation" where the "User cannot access raw data" (Table 3), indicating the algorithm's interpretation delivers the final result.

7. Type of Ground Truth Used

The ground truth used is a combination of:

• Expert Consensus/Reference Methods (Viral Culture + DFA, PCR + Bi-directional Sequencing): This reflects standard laboratory diagnostic methods considered to be gold standards or highly accurate comparators at the time.
  • "True" positives/negatives were determined by these reference methods.
  • For discrepancies, especially for "false positives" or "false negatives" where the FilmArray RP result differed from the initial comparator, further molecular analysis (bi-directional sequence analysis) was often performed, indicating a robust process to confirm ground truth when needed.

8. Sample Size for the Training Set

The document explicitly describes studies for clinical performance evaluation and analytical validation (LoD, inclusivity, specificity, precision, interference). It does not provide details on a specific "training set" or its size, as would be typical for machine learning models. This suggests that the FilmArray RP system's interpretive algorithm (which automatically interprets melting curve analysis results) was developed and validated internally using methods not detailed in this summary (e.g., extensive analytical testing, algorithm tuning, and potentially internal datasets before these formal clinical studies). The "analytical studies" sections (LoD, inclusivity, etc.) would contribute to refining and confirming the algorithm's performance.

9. How the Ground Truth for the Training Set Was Established

Since a "training set" is not explicitly defined or detailed in this summary, the method for establishing its ground truth is also not provided. However, based on the analytical studies described:

• LoD (Limit of Detection): Established by testing limiting dilutions of live, quantified viruses (or clinical specimens in one case) where the presence and concentration are precisely known.
• Analytical Reactivity (Inclusivity): Evaluated using known strains/isolates, often quantified. Bi-directional sequencing and bioinformatics (in silico analyses) were used to confirm specific viral identities and predict reactivity.
• Analytical Specificity (Cross-reactivity and Exclusivity): Tested against high concentrations of known interfering organisms or substances.

These analytical studies established ground truth for known viral identities and concentrations under controlled conditions, which would underpin the fundamental ability of the algorithm to accurately detect and identify targets. While not a "training set" in the modern ML sense, these analytical validations serve a similar purpose in confirming the algorithm's foundational accuracy against known truths.

Ask a specific question about this device

The Joint Biological Agent Identification and Diagnostic System (JBAIDS) Plague Detection Kit is a real-time polymerase chain reaction (PCR) test kit intended for the qualitative in vitro diagnostic (IVD) detection of target DNA sequences of Yersinia pestis. The kit can be used to test human whole blood collected in sodium citrate or sputum collected aseptically from individuals greater than 18 years of age suspected of having septic or pneumonic plague. In addition, positive blood cultures and colonies may be tested. The JBAIDS Plague Target 2 assay is used as a supplementary test only after a positive result with the Target 1 Assay.
The JBAIDS Plague Target 1 and Target 2 assays are run on the JBAIDS instrument using the Diagnostic Wizard. Results are for the presumptive identification of Y. pestis in conjunction with culture and other laboratory tests. The definitive identification of Y. pestis from colony growth, liquid blood culture growth, or from blood or sputum specimens requires additional testing and confirmation procedures in consultation with public health or other authorities for whom reports are required.

The diagnosis of plague must be made based on history, signs, symptoms, exposure likelihood, and other laboratory evidence in addition to the identification of Y. pestis from cultures or directly from whole blood or sputum specimens.

The JBAIDS Plague Detection Kit is intended for use by trained clinical laboratory personnel who have received specific training on the use of the JBAIDS Plague Detection Kit. The level of Y. pestis that would be present in blood or sputum from individuals with early systemic infection is unknown. Due to the difficulty in obtaining clinical specimens, these assays were not evaluated with blood or sputum from individuals with septic or pneumonic plague.

The Joint Biological Agent Identification and Diagnostic System (JBAIDS) Plague Detection Kit is a real-time polymerase chain reaction (PCR) reagent kit, which, when used with the JBAIDS instrument and software, allows the qualitative in vitro diagnostic (IVD) detection of target DNA sequences within the pathogenic bacterium, Yersinia pestis, the causative agent of plague. The kit contains two assays, Plague Target 1 and Target 2, each of which consists of oligonucleotide primers and a fluorescent-labeled target assay probe that specifically detect Y. pestis DNA. The Target 2 assay is reserved for samples that test positive with the Target 1 assay. The kit is designed for use with the JBAIDS instrument, a portable thermocycler and real-time fluorimeter that performs PCR in glass capillaries.

Before testing, samples are purified using Idaho Technology's 1-2-3TM Sample Purification Kits (or validated equivalent). The resulting purified sample is added to an Unknown reagent vial and an Inhibition Control reagent vial, along with reconstitution buffer. When the organism is present, a fragment of Y. pestis DNA is amplified. The amplicon is detected by fluorescence using a specific hydrolysis probe. The hydrolysis probe contains a short oligonucleotide that hybridizes to an internal sequence of the amplified fragment during the annealing phase of the PCR cycle. This probe has the 5' and 3' ends labeled with a reporter dye and a quenching dye, respectively. When the probe hybridizes to the specific DNA target, the Taq polymerase enzyme replicating the target-specific DNA hydrolyzes the probe, separating the two fluorophores and allowing the reporter dye to fluoresce.

The JBAIDS instrument measures the level of fluorescence from each unknown sample and control. JBAIDS Software analyzes the fluorescence amplification curves and reports results as positive, negative, inhibited, or uncertain. A failure of the Positive or Negative Control will result in the entire run being called invalid. Failure of the Inhibition Control yields an inhibited result when the associated sample has a negative result for the target assay and requires retesting of that sample.

Due to the nature of the provided document (a 510(k) summary for a diagnostic test kit), the study performed is a diagnostic accuracy study rather than a study evaluating the performance of an AI/ML device. Therefore, many of the requested fields (MRMC study, effect size of human readers improving with AI, number of experts for ground truth establishment, etc.) are not applicable and will be marked as "N/A".

Here's an analysis of the provided text based on your request:

JBAIDS Plague Detection Kit Performance Study Analysis

1. Table of Acceptance Criteria and Reported Device Performance

The document does not explicitly state "acceptance criteria" for the clinical trial in terms of specific performance metrics that needed to be met for FDA clearance. However, it details the design of the clinical specificity study and the resulting performance. For analytical studies, it provides "LOD" (Limit of Detection) and inclusivity/exclusivity data which serve as performance measures.

2. Sample Size Used for the Test Set and Data Provenance

• Analytical Test Set:
  • Inclusivity: 18 isolates of virulent Y. pestis (subtypes and strains)
  • Exclusivity: A "panel" of 24 isolates (phylogenetically related and unrelated organisms)
  • Data Provenance: Not explicitly stated, but typically research laboratory settings for analytical studies. Retrospective in nature.
• Clinical Test Set:
  • Whole Blood: 132 samples
  • Sputum: 36 samples
  • Data Provenance: The study was a "multisite clinical trial". The samples were obtained from "subjects with clinical signs and symptoms consistent with systemic plague and for whom a blood and/or sputum culture had been ordered." Since clinical plague is rare, and the document explicitly states "Due to the difficulty in obtaining clinical specimens, these assays were not evaluated with blood or sputum from individuals with septic or pneumonic plague," these samples were likely from individuals suspected of plague but ultimately found to be negative. Thus, these are clinical samples, but representative of a "negative" population in the context of plague in humans. Retrospective in nature.

3. Number of Experts Used to Establish the Ground Truth for the Test Set and Their Qualifications

• N/A. For this in vitro diagnostic (IVD) device, the ground truth for analytical studies is established by known bacterial stocks and for clinical studies, by established laboratory culture methods.
• The ground truth for the clinical study was "laboratory culture results" which were considered the "gold standard." These methods are typically performed by trained microbiologists or clinical laboratory scientists, not "experts" in the sense of physicians adjudicating medical imaging or complex interpretations.

4. Adjudication Method for the Test Set

• N/A. For analytical studies, the ground truth (presence/absence of specific bacteria, concentration) is determined by established microbiological methods and known samples, without adjudication.
• For the clinical specificity study, the ground truth was "laboratory culture results." These are typically definitive for bacterial presence/absence. No adjudication among experts is mentioned or typically needed for this type of ground truth.

5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study Was Done

• No. This is an in vitro diagnostic (IVD) device, not an AI/ML device requiring human-in-the-loop performance evaluation. The device provides an automated "positive, negative, inhibited, or uncertain" result.
• Effect size of how much human readers improve with AI vs. without AI assistance: N/A.

6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) Was Done

• Yes, in essence. The JBAIDS system operates as a standalone diagnostic test. The "JBAIDS Software analyzes the fluorescence amplification curves and reports results as positive, negative, inhibited, or uncertain." This is the standalone performance of the analytical system.
• While the kit is "intended for use by trained clinical laboratory personnel," their role is to operate the instrument and interpret the automated results within a clinical context, not to perform a subjective interpretation of a raw signal that the algorithm then enhances.

7. The Type of Ground Truth Used

• Analytical Studies: Known strains/isolates of Y. pestis and other bacteria, with confirmed identification and concentrations (e.g., CFU/mL).
• Clinical Studies: "Laboratory culture results," which are considered the "gold standard" for bacterial identification in clinical samples.

8. The Sample Size for the Training Set

• Not explicitly stated in terms of a "training set." For IVDs, assay development and optimization (which can be considered analogous to training) involve numerous preliminary experiments with various dilutions, strains, and conditions, but these aren't typically documented as a formal "training set" with a defined size in the same way an AI/ML model would. The document describes the assay's design and then its validation/testing.

9. How the Ground Truth for the Training Set Was Established

• N/A (as no formal "training set" is described). However, for the development of PCR assays (like this kit), the ground truth for optimizing primers and probes would be established by:
  • Using purified genomic DNA of Yersinia pestis and other closely related and common organisms.
  • Sequencing to confirm target regions.
  • Utilizing known bacterial cultures and dilutions with confirmed concentrations.
  • These foundational truths are based on established molecular biology and microbiology techniques.

Ask a specific question about this device

The Joint Biological Agent Identification and Diagnostic System (JBAIDS) Tularemia Detection Kit is a real-time polymerase chain reaction (PCR) test system intended for the qualitative in vitro diagnostic (IVD) detection of target DNA sequences of Francisella tularensis. The system can be used to test human whole blood collected in sodium citrate or sputum collected aseptically from individuals greater than 18 years of age suspected of having tularemia. In addition, positive blood cultures and colonies may be tested. This assay is intended to aid in diagnosis of individuals presenting with signs and symptoms of pneumonic or typhoidal tularemia. It is not intended to aid in the diagnosis of glandular, ulceroglandular, oculoglandular, or oropharyngeal tularemia.

The JBAIDS Tularemia Detection Kit is run on the JBAIDS instrument using the Diagnostic Wizard. Results are for the presumptive identification of F. tularensis, in conjunction with culture and other laboratory tests. The definitive identification of F. tularensis from colony growth, liquid blood culture, blood specimens, or sputum specimens requires additional testing and confirmation procedures in consultation with public health or other authorities for whom reports are required.

The diagnosis of tularemia infection must be made based on history, signs, symptoms, exposure likelihood, and other laboratory evidence, in addition to the identification of the target either from colonies, blood culture, whole blood specimens, or sputum specimens.

The JBAIDS Tularemia Detection Kit is intended for use by trained clinical laboratory personnel who have received specific training on the use of the JBAIDS Tularemia Detection kit. The level of F. tularensis that would be present in blood or sputum of individuals with early systemic or pneumonic infection is unknown. Due to the difficulty in obtaining clinical specimens, the assay was not evaluated with blood or sputum from individuals presenting with signs and symptoms of tularemia and who subsequently developed pneumonic or typhoidal tularemia.

The Joint Biological Agent Identification and Diagnostic System (JBAIDS) Tularemia Detection Kit is a real-time polymerase chain reaction (PCR) reagent kit, which, when used with the JBAIDS instrument and software, allows the qualitative in vitro diagnostic (IVD) detection of a target DNA sequence within the pathogenic bacterium, Francisella tularensis, the causative agent of tularemia. Key components of the kit include oligonucleotide primers and a fluorescent-labeled target assay probe that specifically detects F. tularensis DNA. The kit is designed for use with the JBAIDS instrument, a portable thermocycler and real-time fluorimeter that performs PCR in glass capillaries.
Before testing, samples are purified using Idaho Technology's 1-2-37M Sample Purification Kits (or validated equivalent). The resulting purified sample is added to an Unknown reagent vial and an Inhibition Control reagent vial, along with reconstitution buffer. When the organism is present, a fragment of F. tularensis DNA is amplified. The amplicon is detected by fluorescence using a specific hydrolysis probe. The hydrolysis probe contains a short oligonucleotide that hybridizes to an internal sequence of the amplified fragment during the annealing phase of the PCR cycle. This probe has the 5' and 3' ends labeled with a reporter dye and a quenching dye, respectively. When the probe hybridizes to the specific DNA target, the Taq polymerase enzyme replicating the target-specific DNA hydrolyzes the probe, separating the two fluorophores and allowing the reporter dye to fluoresce.

The JBAIDS instrument measures the level of fluorescence from each unknown sample and control. JBAIDS Software analyzes the fluorescence amplification curves and reports results as positive, negative, inhibited, or uncertain. A failure of the Positive or Negative Control will result in the entire run being called invalid. Failure of the Inhibition Control yields an inhibited result when the associated sample has a negative result for the target assay and requires retesting of that sample.

Here's an analysis of the provided text regarding the acceptance criteria and study for the JBAIDS Tularemia Detection Kit, structured according to your request:

1. Table of Acceptance Criteria and Reported Device Performance

2. Sample Size Used for the Test Set and Data Provenance

• Analytical Testing (Inclusivity): 27 isolates of F. tularensis (subtypes and strains).
• Analytical Testing (Exclusivity): 24 organisms (phylogenetically related and unrelated).
• Clinical Specificity Testing:
  • Whole Blood: 132 samples
  • Sputum: 36 samples
• Data Provenance: The document does not explicitly state the country of origin for the clinical samples. It indicates a "multisite clinical trial was conducted," suggesting multiple sites, likely within the United States given it's an FDA submission. The clinical data is retrospective in nature, as it was limited to assessing clinical specificity using samples from individuals suspected of tularemia and for whom culture had been ordered. The submission notes the difficulty in obtaining clinical specimens from individuals with confirmed pneumonic or typhoidal tularemia.

3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications of Those Experts

The document does not specify the number or qualifications of experts used to establish ground truth for the test set.

4. Adjudication Method for the Test Set

The document does not explicitly describe an adjudication method for the test set. For the analytical and clinical studies, the reference method (culture for clinical specificity, identification of known organisms for analytical studies) served as the comparator without detailing an adjudication process for discrepancies.

5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study was Done

No, a Multi-Reader Multi-Case (MRMC) comparative effectiveness study was not done. The device is an in vitro diagnostic (IVD) PCR kit, designed for automated laboratory analysis, not human interpretation of images or other data requiring multiple readers. The study primarily focused on the device's accuracy against a "gold standard" (culture for clinical samples, known strains/organisms for analytical studies).

6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) was done

Yes, a standalone performance study was conducted. The JBAIDS Tularemia Detection Kit is an automated PCR system. The JBAIDS Software "analyzes the fluorescence amplification curves and reports results as positive, negative, inhibited, or uncertain." This indicates that the algorithm itself (the software within the JBAIDS instrument) provides the primary result interpretation, making it a standalone system. The stated advantage of the JBAIDS is that "the JBAIDS software automatically interprets the assay results, reducing the opportunity for user error."

7. The Type of Ground Truth Used

• Analytical Studies (Inclusivity & Exclusivity): Known bacterial isolates and purified DNA from various F. tularensis strains and other organisms. The ground truth was established by the identity of these reference strains/samples.
• Clinical Studies (Specificity): Laboratory culture was used as the "gold standard technique" for the clinical specificity assessment.

8. The Sample Size for the Training Set

The document does not explicitly mention a "training set" in the context of machine learning. As a PCR diagnostic kit, performance characteristics are typically established through analytical validation (inclusivity, exclusivity, precision, etc.) and clinical validation studies, rather than a machine learning training/test set paradigm. Therefore, there's no specified training set for an AI/ML algorithm.

9. How the Ground Truth for the Training Set Was Established

Since no specific training set for an AI/ML algorithm is described, this question is not applicable in the context of this 510(k) submission for a PCR kit. Ground truth for the analytical and clinical validation was established as described in section 7.

Ask a specific question about this device

The JBAIDS Anthrax Detection System is a real-time polymerase chain reaction (PCR) test system intended for the qualitative in vitro diagnostic (IVD) detection of target DNA sequences on the pXO1 plasmid (Target 1) and the pXO2 plasmid (Target 2) from Bacillus anthracis. The system can be used to test human whole blood collected in sodium citrate from individuals suspected of having anthrax, positive blood cultures, and cultured organisms grown on blood agar plates. The JBAIDS Anthrax Target 2 assay is used as a supplementary test only after a positive result with the Target 1 Assay.

The JBAIDS Anthrax Target 1 and Target 2 Assays are run on the JBAIDS instrument using the Diagnostic Wizard.

Results are for the presumptive identification of B. anthracis, in conjunction with culture and other laboratory tests. The following considerations also apply:

• The diagnosis of anthrax infection must be made based on history, signs, symptoms, exposure likelihood, and other laboratory evidence, in addition to the identification of pXO1 and pXO2 targets either from cultures or from direct blood specimens.
• The assays have not been evaluated with blood from individuals without clinical signs or symptoms who were presumed exposed and who subsequently developed anthrax (inhalation or other forms of the disease), or from individuals with any form of anthrax (inhalational, cutaneous, or gastrointestinal).
• The level of plasmid targets that would be present in blood from individuals with early systemic infection is unknown.
• The definitive identification of B. anthracis from colony growth, liquid blood culture growth, or from blood specimens requires additional testing and confirmation procedures in consultation with public health or other authorities for whom reports are required.

The safety and effectiveness of other types of tests or sample types (not identified as "For in vitro diagnostic use") have not been established.

The Joint Biological Agent Identification and Diagnostic System (JBAIDS) Anthrax Detection System is a fully integrated in vitro diagnostic (IVD) system composed of the following:

• JBAIDS instrument with laptop computer
• Software
• Two different freeze-dried reagent assays (in one kit) for the qualitative detection of pathogenic Bacillus anthracis
• Four different sample preparation protocols, two for isolating target DNA from whole blood, one for processing blood culture, and another for processing colonies.

The JBAIDS instrument, using Polymerase Chain Reaction (PCR) technology, is a portable thermocycler and real-time fluorimeter. The JBAIDS Anthrax Detection Kit is specially designed for PCR in glass capillaries using the JBAIDS instrument and hydrolysis probes for sequence-specific detection of B. anthracis DNA found on the pX01 plasmid (Target 1) and the pX02 plasmid (Target 2).

The reagent kit contains four different types of freeze-dried reagent vials: Positive Controls, Negative Controls, Inhibition Controls, and Unknowns (used for testing the patient sample). Each JBAIDS assay requires a Positive and Negative Control, and each sample is tested using both an Inhibition Control vial and an Unknown reagent vial.

Before testing, whole-blood samples are purified using the Idaho Technology IT 1-2-3 FLOW or QFLOWdir Sample Purification Kit (or validated equivalent), while blood culture and direct culture specimens are prepared using the IT 1-2-3 SWIPE Sample Purification Kit (or validated equivalent). The resulting purified sample is added to an Unknown reagent vial and an Inhibition Control reagent vial, along with reconstitution buffer. A Positive Control and a Negative Control vial are prepared using reconstitution buffer and reagent grade water. Aliquots from each reagent vial are transferred to two reaction capillaries that are tested together in the JBAIDS instrument. The instrument is programmed to perform heating and cooling cycles that drive the PCR process. The heating and cooling cycles are generated using a heating coil and varying fan speeds. Fluorescence emission is monitored over one of three wavelengths, and the instrument software interprets the change in fluorescence to determine whether the target DNA is present.

When the organism is present, a fragment of B. anthracis DNA is amplified using specific primers. The amplicon is detected by fluorescence using a specific hydrolysis probe. The hydrolysis probe contains a short oligonucleotide that hybridizes to an internal sequence of the amplified fragment during the annealing phase of the PCR cycle. This probe has the 5' and 3' ends labeled with a reporter dye and a quenching dye, respectively. When the probe hybridizes to the specific DNA target, the Taq polymerase enzyme, replicating the target-specific DNA, hydrolyzes the probe, which separates the two fluorophores, thus allowing the reporter dye to fluoresce.

The level of fluorescence from each unknown sample and control is measured by the JBAIDS instrument. JBAIDS Software analyzes fluorescence amplification curves and reports results as "Positive," "Negative," "Inhibited," or "Uncertain." A failure of the Positive or Negative Control will result in the entire run being called "Invalid." Failure of the Inhibition Control yields an Inhibited result for the associated sample and requires retesting of that sample.

The JBAIDS Anthrax Detection System is a real-time PCR test system intended for the qualitative in vitro diagnostic (IVD) detection of target DNA sequences on the pXO1 plasmid (Target 1) and the pXO2 plasmid (Target 2) from Bacillus anthracis.

1. Acceptance Criteria and Reported Device Performance:

The provided document describes a method comparison and carry-over study rather than specific acceptance criteria thresholds with a pass/fail outcome. The studies aim to demonstrate equivalence between a new sample purification kit (IT 1-2-3 QFLOWdna) and an existing one (IT 1-2-3 FLOW).

2. Sample Sizes and Data Provenance:

• Method Comparison - Spiked Samples: 6 citrated whole blood samples spiked with B. anthracis at the Limit of Detection (LOD).
• Method Comparison - Negative Samples: 16 normal healthy donors (citrated whole blood samples).
• Carry-over Study:
  • Strongly positive samples (spiked at 5 x 10" CFU/mL) processed next to negative (unspiked) samples.
  • QFLOW™ protocol: 42 negative capillaries were assessed for carry-over.
  • IT 1-2-3 FLOW protocol: 12 negative capillaries were assessed for carry-over.
• Data Provenance: Not explicitly stated (e.g., country of origin). The studies appear to be prospective as they were specifically performed to evaluate the new sample purification kit.

3. Number of Experts and Qualifications for Ground Truth: No information provided. This is a molecular diagnostic test, and ground truth would typically be established based on the known spiked concentration of B. anthracis or confirmed negative status of healthy donor samples, rather than expert interpretation of images or clinical data.

4. Adjudication Method: Not applicable. For this type of molecular test, objective results (positive/negative/inhibited) are generated by the instrument based on fluorescence curves and software analysis, not human interpretation requiring adjudication.

5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study: No. This is not an imaging device or one that relies on human interpretation for diagnosis; therefore, an MRMC study comparing human readers with and without AI assistance is not applicable.

6. Standalone Performance: Yes, the device's performance results (detection of B. anthracis DNA, specificity in negative samples, carry-over rate) are reported for the algorithm (JBAIDS Anthrax Detection System) based on its analysis of samples. The system reports "Positive," "Negative," "Inhibited," or "Uncertain" results without human intervention in the interpretation of the raw data.

7. Type of Ground Truth Used:

• For the method comparison using spiked samples: The ground truth was based on the known presence of B. anthracis DNA at a defined concentration (LOD).
• For the method comparison using healthy donor samples: The ground truth was the known absence of B. anthracis DNA in these healthy individuals.
• For the carry-over study: The ground truth for positive samples was their known high concentration of B. anthracis, and for negative samples, it was the known absence of B. anthracis.

8. Sample Size for the Training Set: Not specified. This document describes performance validation for a specific modification (new sample purification kit) rather than the initial development and training of the PCR assay's core algorithms. PCR assays are typically developed based on laboratory experiments to define primer/probe specificity and amplification efficiency, rather than machine learning on a "training set" in the traditional sense.

9. How the Ground Truth for the Training Set Was Established: Not specified. As mentioned above, for a PCR assay, "training" involves optimizing molecular biology parameters, and ground truth is based on known biological characteristics of the target organism and non-target organisms.

Ask a specific question about this device

The JBAIDS Anthrax Detection System is a real-time polymerase chain reaction (PCR) test system intended for the qualitative in vitro diagnostic (IVD) detection of target DNA sequences on the pXO1 plasmid (Target 1) and the pXO2 plasmid (Target 2) from Bacillus anthracis. The system can be used to test human whole blood collected in sodium citrate from individuals suspected of having anthrax, positive blood cultures, and cultured organisms grown on blood agar plates. The JBAIDS Anthrax Target 2 assay is used as a supplementary test only after a positive result with the Target 1 Assay.
The JBAIDS Anthrax Target 1 and Target 2 Assays are run on the JBAIDS instrument using the Diagnostic Wizard.
Results are for the presumptive identification of B. anthracis, in conjunction with culture and other laboratory tests. The following considerations also apply:

• The diagnosis of anthrax infection must be made based on history, signs, symptoms, exposure likelihood, other laboratory evidence, in addition to the identification of pXO1 and pXO2 targets either from cultures or from direct blood specimens.
• The assays have not been evaluated with blood from individuals without clinical signs or symptoms who were presumed exposed and who subsequently developed anthrax (inhalation or other forms of the disease), or from individuals with any form of anthrax (inhalational, cutaneous, or gastrointestinal).
• The level of plasmid targets that would be present in blood from individuals with early systemic infection is unknown.
• The definitive identification of B. anthracis from colony growth, liquid blood culture growth, or from blood specimens requires additional testing and confirmation procedures in consultation with public health or other authorities for whom reports are required.
  The safety and effectiveness of other types of tests or sample types (not identified as "For in vitro diagnostic use") have not been established.

The Joint Biological Agent Identification and Diagnostic System (JBAIDS) Device Anthrax Detection System is a fully integrated in-vitro diagnostic (IVD) system composed of the JBAIDS instrument with laptop computer, software, 2 different freeze-dried reagent assays (in one kit) for the qualitative detection of pathogenic Bacillus anthracis, and 3 different sample preparation protocols for isolating target DNA from whole blood, blood culture, or direct culture.
The JBAIDS instrument, using Polymerase Chain Reaction (PCR) technology, is a portable thermocycler and real-time fluorimeter. The JBAIDS Anthrax Detection Kit is specially designed for PCR in glass capillaries using the JBAIDS instrument and hydrolysis probes for detection of the pXO1 plasmid (Target 1) and the pXO2 plasmid (Target 2) DNA sequences. A fragment of plasmid DNA is amplified using specific primers, creating amplicon. The amplicon is detected using a specific hydrolysis probe, which is a short oligonucleotide that hybridizes to an internal sequence of the amplified fragment during the annealing phase of the PCR cycle. This probe has the 5' and 3' ends labeled with a reporter dye and a quenching dye, respectively. When the probe hybridizes to the specific DNA target, the Taq polymerase enzyme replicating the target-specific DNA hydrolyzes the probe, separating the two fluorophores, thus allowing the reporter dye to fluoresce.
The reagent kit contains 4 different types of freeze-dried reagent vials: Positive Controls, Negative Controls, Inhibition Controls, and Unknowns (used for testing the patient sample). Each JBAIDS run requires a Positive and Negative Control, and each sample is tested using both an Inhibition Control vial and an Unknown reagent vial. The characteristics of the amplification curves from the positive control (PC), negative control (NC), inhibition controls (IC) and from each unknown sample are analyzed by the JBAIDS Software, and results are reported as Positive. Negative, Inhibited or Uncertain. When PCs or NCs are unacceptable, the test results for all samples in the JBAIDS run are considered invalid and must be repeated.
Prior to testing, whole-blood samples are purified using the Idaho Technology IT 1-2-37M FLOW Sample Purification Kit (or validated equivalent), while blood culture and direct culture specimens are prepared using the IT 1-2-31M SWIPE Sample Purification Kit (or validated equivalent). The resulting purified sample is added to an Unknown reagent vial and an Inhibition Control reagent vial, along with reconstitution buffer.

Here's an analysis of the acceptance criteria and the study that proves the device meets them, based on the provided text:

JBAIDS Anthrax Detection System Acceptance Criteria and Study Details

1. Table of Acceptance Criteria and Reported Device Performance

The provided document does not explicitly state formal "acceptance criteria" with numerical thresholds for sensitivity and specificity in a table format for the JBAIDS Anthrax Detection System. Instead, it describes performance characteristics that demonstrate substantial equivalence to a predicate device and good analytical and clinical performance. The closest interpretation of acceptance criteria would be that the device needs to achieve high sensitivity and specificity in detecting B. anthracis targets, similar to or exceeding the predicate method.

Here's a summary of the stated performance:

• Direct Culture Panel: 23/23 (100%) detected
• Blood Culture Panel: 11/11 (100%) detected
• Whole Blood Spiked Samples: 67/68 (98.5%) detected (at limit of detection levels) |
  | Analytical Specificity: | No cross-reactivity with non-B. anthracis organisms |
• Direct Culture Panel: 34/37 (91.9%) negative for non-B. anthracis strains
• Blood Culture Panel: 12/12 (100%) negative for non-B. anthracis strains
• Note: Cross-reacted with 3 virulent B. cereus strains known to cause anthrax-like illness. |
  | Clinical Specificity: | No false positives in samples from individuals suspected of anthrax (but without confirmed anthrax) | 150/150 (100%) negative in blood samples from hospitalized subjects (95% CI, 98%-100%) |
  | Equivalence to Predicate (CDC Gamma Phage Lysis Assay): | As effective as predicate, with additional benefits | "As effective as the predicate assay," "easier to use," "highly sensitive and specific." |

2. Sample Sizes and Data Provenance

The provided document indicates the following sample sizes and data provenance:

• Test Set (Analytical Studies):

  • Direct Culture Panel: 23 virulent B. anthracis strains (positive detection) + 37 non-B. anthracis strains (negative detection) = 60 samples.
  • Blood Culture Panel: 11 virulent B. anthracis strains (positive detection) + 12 non-B. anthracis strains (negative detection) = 23 samples.
  • Whole Blood Spiked Samples: 68 samples spiked with limit of detection levels of live B. anthracis.
  • Data Provenance: The document does not explicitly state the country of origin. It refers to "virulent strains of B. anthracis tested" and "non-B. anthracis strains." Given the context of CDC involvement and FDA submission, it's highly likely these were laboratory-controlled samples and reference strains, possibly from a national or international repository, and not necessarily patient data from a specific country. This appears to be retrospective testing of characterized samples.

• Test Set (Clinical Specificity Study):

  • Sample Size: 150 blood samples.
  • Data Provenance: "Blood samples from hospitalized subjects with clinical signs and symptoms consistent with inhalation or systemic anthrax and for whom a blood culture had been ordered." This indicates a prospective data collection from a clinical setting, presumably within the US. The document does not specify the exact location(s).

3. Number of Experts and Qualifications for Ground Truth

The document does not explicitly state the number of experts used or their specific qualifications (e.g., "radiologist with 10 years of experience") for establishing ground truth in a systematic way for the test set.

However, for the predicate device and confirmation methods:

• Predicate Method: The predicate for the JBAIDS Anthrax Detection Kit is "traditional microbiological identification of the organism (preamendment methods) with confirmation by the Centers for Disease Control Laboratory Response Network Gamma Phage Lysis assay." This implies that the ground truth for B. anthracis identification was established by microbiologists and experts within the CDC's Laboratory Response Network, following standard microbiological identification criteria and the gamma phage lysis assay procedure.
• Confirmation for Analytical Studies: For the direct culture and blood culture panels, "all of the samples were confirmed as B. anthracis using standard biochemical identification and tested positive using the CDC Reference Laboratory Procedure for Identification of B. anthracis Using Lysis by Gamma Phage." This again points to verification by microbiology experts using established CDC protocols.

4. Adjudication Method for the Test Set

The document does not describe an explicit adjudication method (e.g., 2+1, 3+1). The ground truth for the analytical studies was established by standard biochemical identification and the CDC Reference Laboratory Procedure for Identification of B. anthracis Using Lysis by Gamma Phage, which are definitive laboratory methods rather than subjective expert consensus requiring adjudication.

For the clinical specificity study, the ground truth for ruling out anthrax was "not identified in any of the blood cultures." This implies a definitive laboratory result rather than a consensus decision requiring adjudication.

5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study

No, a Multi-Reader Multi-Case (MRMC) comparative effectiveness study was not done. The JBAIDS Anthrax Detection System is an in-vitro diagnostic (IVD) PCR system that provides an automated result (Positive, Negative, Inhibited, Uncertain). It's an algorithm-only device without a human-in-the-loop component in its primary function, thus improvements in human reader performance with or without AI assistance are not applicable.

6. Standalone (Algorithm Only) Performance

Yes, a standalone (algorithm only) performance study was done for the JBAIDS Anthrax Detection System. The device itself is an automated system that uses PCR technology to detect specific DNA sequences and its software then analyzes the amplification curves and reports results as Positive, Negative, Inhibited, or Uncertain (as described in the "Description" section).

The performance metrics reported (sensitivity, specificity, detection rates for various samples) are directly from the JBAIDS system's automated output.

7. Type of Ground Truth Used

The ground truth used was:

• Microbiological Identification/Pathology: For the analytical studies, ground truth for B. anthracis presence was established by "standard biochemical identification and ... the CDC Reference Laboratory Procedure for Identification of B. anthracis Using Lysis by Gamma Phage." For non-B. anthracis strains, their identification as non-anthrax was also based on standard microbiological characterization.
• Outcomes Data (Indirect/Surrogate): For the clinical specificity study, the ground truth for the absence of anthrax was based on "blood cultures" being negative for B. anthracis. This serves as a clinical outcome surrogate to confirm the absence of the infection in symptomatic patients.

8. Sample Size for the Training Set

The document does not specify the sample size for a training set. This is common for PCR-based IVD systems, where the "training" (development and optimization) often relies on well-characterized laboratory strains and known genetic sequences rather than a distinct "training set" in the machine learning sense. The device is designed to detect known specific DNA sequences rather than learn patterns from a broad dataset.

9. How Ground Truth for the Training Set Was Established

As no specific "training set" is mentioned, the method for establishing ground truth for training data is not provided. However, the development of the assays (e.g., designing primers and probes for pXO1 and pXO2) would rely on the established genomic sequences of B. anthracis, confirmed by techniques such as genomic sequencing, traditional microbiological identification, and confirmed virulence studies from expert laboratories like the CDC. The document highlights that the targets (pXO1 and pXO2 plasmids) are "essential for the organism's pathogenicity," implicitly referencing well-established biological facts about B. anthracis.

Ask a specific question about this device